(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer session included a presentation by Dr. David McDermott discussing long-term outcomes in the KEYNOTE-427 Cohort A trial of pembrolizumab monotherapy for first-line treatment of advanced renal cell carcinoma (RCC). A number of combination therapies involving immune checkpoint inhibitors, including the PD-1 inhibitor pembrolizumab, have shown antitumor activity as first-line treatment of advanced RCC. In the open-label, single-arm, phase II KEYNOTE-427 study (NCT02853344), first-line pembrolizumab monotherapy showed antitumor activity in patients with advanced clear cell RCC (cohort A).1 At the 2021 ESMO congress, Dr. McDermott and colleagues presented updated efficacy and safety results after a minimum of 41 months of follow-up for patients with clear cell RCC.